We looked at the impact of delayed splenic artery occlusion (SAO) on recipients with established small-for-size syndrome (SFSS) after partial graft liver transplantation [either from a living donor (LD) or split from a deceased donor (DD)]. Between 1999 and 2007 we performed a total of 100 partial l
Splenic artery embolization for the treatment of refractory ascites after liver transplantation
β Scribed by Cristiano Quintini; Giuseppe D'Amico; Chase Brown; Federico Aucejo; Koji Hashimoto; Dympna M. Kelly; Bijan Eghtesad; Mark Sands; John J. Fung; Charles M. Miller
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 283 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.22280
No coin nor oath required. For personal study only.
β¦ Synopsis
Refractory ascites (RA) is a challenging complication after orthotopic liver transplantation. Its treatment consists of the removal of the precipitating factors. When the etiology is unknown, supportive treatment can be attempted. In severe cases, transjugular intrahepatic portosystemic shunts, portocaval shunts, and liver retransplantation have been used with marginal results. Recently, splenic artery embolization (SAE) has been described as an effective procedure for reducing portal hyperperfusion in patients undergoing partial or whole liver transplantation. Here we describe our experience with SAE for the treatment of RA. Between June 2004 and June 2010, 6 patients underwent proximal SAE for RA. Intraoperative flow measurements, graft characteristics, embolization portal vein (PV) velocities before and after SAE, and spleen/liver volume ratios were collected and analyzed. The response to treatment was assessed with imaging (ultrasound/computed tomography) and on the basis of clinical outcomes (weight changes, diuretic requirements, and the time to ascites resolution). The PV velocity decreased significantly for each patient after the embolization (median ΒΌ 66.5 cm/second before SAE and median ΒΌ 27.5 cm/second after SAE, P < 0.01). All patients experienced a significant postprocedural weight loss (mean ΒΌ 88.1 6 28.4 kg before SAE and mean ΒΌ 75.8 6 28.4 kg after SAE, P < 0.01) and a dramatic decrease in their diuretic requirements. All but 1 of the patients experienced a complete resolution of ascites after a median time of 49.5 days (range ΒΌ 12-295 days). No patient presented with postembolization complications. In conclusion, SAE was effective in reducing the PV velocity immediately after the procedure. Clinically, this translated into a dramatic weight loss, a reduction of diuretic use, and a resolution of ascites. SAE appears to be a safe and effective treatment for RA.
π SIMILAR VOLUMES
Recurrent venous thrombosis following liver transplantation for Budd-Chiari syndrome is common, particularly in the setting of an underlying myeloproliferative disorder. We describe a patient who developed refractory ascites due to portal vein thrombosis following liver transplantation for Budd-Chia
## H epatitis C virus (HCV)-related cirrhosis is currently the leading indication for liver transplantation in Europe and in the United States. 1,2 HCV recurrence after transplantation is almost universal, and 60%-90% of patients will develop lesions of chronic hepatitis C on the graft. 3 The cour
Previous data have suggested that the nonsystemic antibiotic rifaximin may be effective for the treatment of Clostridium difficile infection (CDI). This single-center retrospective study evaluated the efficacy of rifaximin for the treatment of CDI refractory to standard treatments in patients who ha
The aim of this study was to compare nifedipine and carvedilol in the treatment of de novo arterial hypertension after orthotopic liver transplantation (OLT). The study included 50 patients who developed arterial hypertension after OLT. Twenty-five patients received nifedipine (group A), and 25 rece